You just read:

Capricor Therapeutics to Present Six-Month Results from the Randomized HOPE Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society

News provided by

Capricor Therapeutics, Inc.

Sep 18, 2017, 07:00 ET